Notable’s Post

Our mission is to develop therapeutics that work predictably for people fighting cancer. For many people, a cancer diagnosis is quickly followed by nerve-wracking choices about treatment options. Notable is dedicated to developing therapeutics so that physicians will know whether a patient is likely to benefit before they recommend a treatment.  #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline

Radiopharmaceuticals are emerging as a powerful avenue for treating cancer. In this interview, Dr Jack Hoppin and Dr John Babich, Ratio Therapeutics, talk specifically how the therapy can combine with immuno-oncology to enhance activity and efficacy, for patient benefit. "You have the opportunity to not only reduce tumor burden and control tumor growth, but also stimulate inflammation locally on every site that the radioactivity lands on." Read the full interview here: https://lnkd.in/e7iG9WHX #IO360Summit #immunooncology #radiopharmaceuticals

🤒 Chemotherapy's Limited Effectiveness for Pancreatic Cancer 🤒 #shorts Discover why chemotherapy is less effective for pancreatic cancer compared to other cancers, according to an experienced medical expert. #PancreaticCancer #Chemotherapy #CancerTreatment #medicalinsights #CloudHospital You can connect with this clinic through the following link: https://lnkd.in/dMQ3g7DM

Big Pharma’s interest for antibody-drug conjugates (ADCs) is skyrocketing. The increased volume in dealmaking reflects the potential of #ADC as a targeted #cancer therapy—and investments are expected to carry on as the modality continues to build up clinical and commercial acceptance. Explore Pharma top 10 companies’ favourite therapeutic areas and drug modalities for M&A in our latest report: https://lnkd.in/d8SXc-v7

Endevica Bio to Start Phase 2 Clinical Trial of Drug to Prevent Weight Loss in Cancer Patients https://lnkd.in/gyE2Qdp7 A peptide called TCMCB07 will be administered to patients who are diagnosed with stage 4 metastatic colorectal cancer and will undergo chemotherapy. NORTHBROOK, Ill., Dec. 20, 2024 /PRNewswire/ — Endevica Bio, a privately held company [...]

The so-called CAR-T cell therapies are among the most innovative therapy options for malignant blood cancers, for example. They require the patient’s living cells, which are then prepared in a special way using an intricate process. The entire production process for these cell-based therapeutics is extremely complex and logistically challenging, making therapeutic applications expensive and limiting their accessibility. Fresenius Kabi is developing and producing two new devices that are essential to the CAR-T cell therapy process. Read more in our story about how the cell processing systems Lovo and Cue are revolutionizing the treatment of cancer patients by making the therapy production more efficient and accessible: 👉 https://lnkd.in/eCgJWChF #Cancer #CARTCellTherapy #CommittedToLife

🚀Revolutionizing Prostate Cancer Theranostics!🚀 Discover groundbreaking advancements in prostate cancer theranostics, merging therapy and diagnostics to improve patient outcomes.🧬 This innovative approach is paving the way for precision medicine and enhanced cancer care.💊 Shuttle Pharmaceuticals, Inc. Mr. Peter Dritschilo, Mr. Michael Vander Hoek Know complete story - https://lnkd.in/dnQT_asf #ProstateCancer #Theranostics #PrecisionMedicine #CancerCare #PharmaInnovation

Antibody drug conjugates (ADCs) are a more targeted treatment for #breastcancer, but what do they mean for patients? ADCs can help deliver a more potent dose of chemotherapy drugs to tumors without damaging surrounding healthy cells, but do they also cause side effects? Learn about the history of ADCs and how they are revolutionizing breast cancer treatment. Read more here: https://bit.ly/4gcrhut

Adjuvant therapy and combination therapy leverage the strengths of different treatments to provide a more robust and comprehensive approach to cancer care. By targeting multiple pathways, reducing resistance, lowering dosages, and addressing tumor heterogeneity, these strategies offer improved efficacy and outcomes compared to mono-therapy. Below is an example!

There is a new actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma. Claudin18.2 (CLDN18.2) is a new biomarker with a targeted therapy to treat gastric/GEJ cancer and can improve the outcome for patients. To learn how CLDN18.2 testing can enhance care and help your patients, visit: https://lnkd.in/gdhNUNyk #Gastric #Adenocarcinoma #Claudin182